Person: KOCAKAYA, DERYA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KOCAKAYA
First Name
DERYA
Name
87 results
Search Results
Now showing 1 - 10 of 87
Publication Metadata only Does preexisting immuncompromised status prevent mortality in COVID-19 patients: friend or foe?(2022-09-01) VEZİR, DUYGU; KOCAKAYA, DERYA; MERCANCI, ZEYNEP; KARAKURT, SAİT; Vezir D., Yildizeli S. O., KOCAKAYA D., Mercanci Z., Balcan B., Cinar C., Eryuksel E., KARAKURT S.Publication Open Access Lung cavitation as a long-term imaging pattern of covid-19(2023-06-01) KOCAKAYA, DERYA; Çınar C., Kocakaya D., Olgun Yıldızeli S., Karakurt S.Background A wide variety of radiological imaging findings, especially CT findings, have been reported in patients with COVID-19 pneumonia during the pandemic surge. Generally, on control chest imaging, individuals who have been cured of the disease usually show complete remission; however, in severe cases, residual pulmonary fibrosis, other abnormalities, and, rarely, lung cavitation can be observed. In this retrospective descriptive study, we aimed to describe the clinical, radiological, and laboratory characteristics of patients who developed lung cavitation in the course of SARS-CoV-2 disease recovery. Methodology Over a period of five months from March 1, 2021, to August 1, 2021, 15 consecutive patients who developed cavitary lesions on chest CT during the course of recovery from COVID-19 were recruited as the study population. All patients had a history of a SARS-CoV-2 infection diagnosed with a positive real-time polymerase chain reaction test. Patients who already had cavitary lesions in chest CT during the start of COVID-19 symptoms were excluded. Results In this study, 14 patients were male (93.3%). The only female patient was the only severely obese patient in the study population, with a body mass index was 40.4 kg/m2 . The median (range) age of the patient population was 61 (42-79) years. Eight patients (53.3%) required intensive care unit admission during the hospitalization period. Three patients who required intensive care unit were intubated and needed invasive mechanical ventilation. Two patients died during hospitalization. Conclusions Lung cavitation remains a rare occurrence in the course of COVID-19. Bronchoscopic evaluation and scanning for pulmonary embolism should be done in appropriate patients to determine secondary reasons for cavitation. Although this descriptive study showed that cavitary lesions can develop in patients with severe disease, more comprehensive studies with a control group are needed to reach a definitive conclusion.Publication Metadata only QT interval prolongation related to afatinib treatment in a patient with metastatic non-small-cell lung cancer(MOSBY-ELSEVIER, 2020) KOCAKAYA, DERYA; Demircan, Nazim Can; Telli, Tugba Akin; Tuylu, Tugba Basoglu; Arikan, Rukiye; Kocakaya, Derya; Sahin, Ahmet Anil; Ercelep, Ozlem; Dane, Faysal; Yumuk, Perran FuldenAfatinib improves survival in metastatic non-small-cell lung cancer driven by activating epidermal growth factor receptor mutations. QT interval prolongation is a possible side effect of tar geted anticancer drugs, but this has not been reported before with afatinib. We report a case of metastatic pulmonary adenocarcinoma with epidermal growth factor receptor exon 19 deletion who was treated with first-line afatinib. The patient was started on afatinib with a total dose of 40 mg/day and experienced grade 3 (> 500 ms) QT interval prolongation in the seventh week. Dose was interrupted and then reduced to 30 mg/day after the event repeated. QT prolongation occurred only once with the reduced dose and radiologic oligoprogression was detected. Local therapy was performed and afatinib was continued as 30 mg/day. To the best of our knowledge, this case marks the first QT interval prolongation associated with afatinib. It is prudent to perform a baseline cardiologic evaluation and electrocardiogram monitoring in non-small cell lung cancer patients treated with this drug. (c) 2020 Elsevier Inc. All rights reserved.Publication Metadata only Pulmonary hypertension classification based on machine learning using standart chest x-ray : ata artificial intelligence study-1(2022-05-26) KOCAKAYA, DERYA; YILDIZELİ, BEDRETTİN; KIVRAK T., YAĞMUR B., ÇİÇEK YILMAZ D., YEŞİL E., ÇELİK A., YAYLA Ç., TEKİN TAK B., İYİGÜN U., ARABACI H. O. , SİNAN Ü. Y. , et al.Amaç: An accurate diagnosis of pulmonary hypertension (PH) is crucial to ensure that patients receive timely treatment. One of the used imaging models to detect pulmonary hypertension is the X-ray. Therefore, a new automated PH type classification model has been presented to depict the separation ability of deep learning for PH types Yöntem: We retrospectively enrolled 6642 images of patients with PH and the control group. A new X-ray image dataset was collected from a multicenter in this work.A transfer learning-based image classification model has been presented in classifying PH types. Bulgular: Our proposed model was applied to the collected dataset, and this dataset contains six categories (five PH and a nonPH). The presented deep feature engineering (computer vision) model attained 86.14% accuracy on this dataset. According to the extracted ROC curve, the average area under the curve rate has been calculated at 0.945.Publication Open Access Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients— case series(2022-01-01) AKSOY, AYSUN; BOZKURTLAR, EMİNE; KARAKURT, SAİT; ERYÜKSEL, SEMİHA EMEL; İNANÇ, GÜZİDE NEVSUN; KOCAKAYA, DERYA; AKSOY A., KOCAKAYA D., Yalçinkaya Y., BOZKURTLAR E., KARAKURT S., Eryüksel E., İnanç N.© TÜBİTAK.Background/aim: Rheumatoid pulmonary nodule can be detected in up to 32% of rheumatoid arthritis (RA) patients and approximately one-third of nodules may cavitate. We aimed to evaluate characteristics of patients with RA developing cavitary pulmonary nodular (CPN) lesions under disease-modifying antirheumatic drugs (DMARDs), follow-up of both cavitary and solid nodules, and their outcome with the treatment. Materials and methods: RA patients who presented with CPN lesions during follow-up were recruited retrospectively in this case series analysis. Total numbers and mean diameters of cavitary and solid nodules in each thorax computed tomography (CT) have been determined and followed up by two experienced pulmonary physicians. Moreover, changes in treatment after the development of the CPN lesions and characteristics of cavitary nodules were collected. Results: Eleven patients with CPN lesions were reported. At the time of CPN diagnosis, more patients were taking leflunomide than methotrexate (81% vs 19%). Half of the patients were receiving biologic therapy and only 18% were taking anti-TNF drugs. After a median of 24 (3–65) months of follow-up, the regression of CPN lesions was determined in 45% (5/11) of patients. Four of these 5 (80%) patients were switched to a treatment regimen without leflunomide and three of them to nonanti-TNF biologic treatment or targeted synthetic DMARDs (tocilizumab, tofacitinib, and rituximab). Conclusion: CPN lesions seen in RA patients are often pulmonary manifestations of the underlying disease; however, one must rule out malignancies or infections. If lesions progress under DMARDs, it is advised to discontinue synthetic DMARDs (LEF/MTX) and switch to another biological DMARD with different modes of action.Publication Metadata only Predictors of health related quality of life in patients wi̇th pulmonary hypertension(2022-02-07) KOCAKAYA, DERYA; ATAŞ, HALİL; YILDIZELİ, BEDRETTİN; MUTLU, BÜLENT; KOCAKAYA D., ŞİŞMAN A., AKASLAN D., ATAŞ H., YILDIZELİ B., MUTLU B.Publication Metadata only İlerı ve son evre akciğer hastalığına ikincil solunum yetmezliği olan hastaların bakım verenlerinde bakım verici yükü ve depresyon ilişkisi(2018-04-18) OLGUN YILDIZELİ, ŞEHNAZ; KASAPOĞLU, UMUT SABRİ; KOCAKAYA, DERYA; ERYÜKSEL, SEMİHA EMEL; CEYHAN, BERRİN; KARAKURT, SAİT; ARIKAN, HÜSEYİN; OLGUN YILDIZELİ Ş., ARIKAN H., KASAPOĞLU U. S., KOCAKAYA D., ERYÜKSEL S. E., CEYHAN B., KARAKURT S.Publication Metadata only Histopathological evaluation of post-mortem pulmonary specimens excised from ICU patients with COVID-19: Do we know what we do not know(2023-05-06) ERMERAK, NEZİH ONUR; BOZKURTLAR, EMİNE; KOCAKAYA, DERYA; GÜL, FETHİ; KARAKURT, SAİT; ERMERAK N. O., BOZKURTLAR E., KOCAKAYA D., GÜL F., KARAKURT S., Cinel I.Publication Open Access The role of procalcitonin as a biomarker for acute pulmonary exacerbation in subjects with cystic fibrosis and non-cystic fibrosis bronchiectasis(2022-01-01) KOCAKAYA, DERYA; ARIKAN, HÜSEYİN; ERYÜKSEL, SEMİHA EMEL; CEYHAN, BERRİN; Mammadov F., Olgun Yildizel S., Kocakaya D., ARIKAN H., Cinar C., Eryuksel E., CEYHAN B.Objective: Patients with cystic fibrosis (CF) and non-CF bronchiectasis are prone to exacerbations of pulmonary infections. C-reactive protein (CRP) and procalcitonin (PCT) are inflammatory markers. The aim of this study is to evaluate the role of CRP and PCT on exacerbations of CF and non-CF bronchiectasis. Patients and Methods: The medical records of 18 CF (52 hospitalizations) and 20 non-CF bronchiectasis patients (51 hospitalizations) were reviewed retrospectively. CRP, PCT levels and, white blood cell (WBC) counts on admission and follow-up were evaluated. Results: C-reactive protein levels correlated with PCT levels on admission in all patients. Baseline PCT levels were markedly higher (>0.5µg/L) in 12% of CF and 10% of non-CF bronchiectasis patients, however, baseline CRP values were markedly higher (>5mg/L) in 96% of CF and non-CF bronchiectasis patients (p=0.760 and p=0.100, respectively). Baseline CRP and PCT levels were positively correlated with hospitalization length (r=0.501, p=0.001 and r=0.289, p=0.04, respectively) in CF patients, but not in non-CF bronchiectasis. Conclusion: Our study shows the potential utility of these biomarkers to determine the severity of the exacerbation particularly predicting hospitalization length in CF patients. Both biomarkers could be able to guide antibiotic treatment of infective exacerbations in CF and non-CF bronchiectasis patients.Publication Metadata only Eri̇şki̇n ki̇sti̇k fi̇brozi̇s hastalarinda İlaç uyumu ve anksi̇yete/depresyonu etki̇leyen faktörler(2018-05-18) KOCAKAYA, DERYA; OLGUN YILDIZELİ, ŞEHNAZ; CEYHAN, BERRİN; USLU N. Z. , KOCAKAYA D., OLGUN YILDIZELİ Ş., CEYHAN B.